David Steinberg
Stock Analyst at Jefferies
(2.93)
# 1,608
Out of 5,064 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $6.03 | +32.67% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $12.64 | +398.42% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $45.32 | -11.74% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $176.93 | +6.26% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $12.24 | -34.64% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $4.92 | +306.50% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $6.03
Upside: +32.67%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $12.64
Upside: +398.42%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $45.32
Upside: -11.74%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $176.93
Upside: +6.26%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $12.24
Upside: -34.64%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $4.92
Upside: +306.50%